REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
381.71
+5.85 (+1.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close375.86
Open374.47
Bid375.00 x 1500
Ask382.56 x 100
Day's Range373.27 - 383.95
52 Week Range340.09 - 543.55
Volume842,220
Avg. Volume840,587
Market Cap40.8B
Beta1.45
PE Ratio (TTM)34.61
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer's lightning round: People might be bailing on Rege...
    CNBC Videos12 days ago

    Cramer's lightning round: People might be bailing on Rege...

    Jim Cramer zoomed through his take on callers' favorite stocks, including a pharmaceutical name spooking investors.

  • Regeneron CEO talks drug pricing and tax reform
    CNBC Videos14 days ago

    Regeneron CEO talks drug pricing and tax reform

    CNBC's Meg Tirrell speaks with Leonard Schleifer, Regeneron CEO, about how the company will benefit from tax cuts, as well as pricing competition among drug companies.

  • 3 Ways to trade biotech
    CNBC Videos14 days ago

    3 Ways to trade biotech

    The "Fast Money" traders give you 3 ways to trade biotech during the J.P. Morgan healthcare conference in San Francisco.

  • Regeneron's Dupixent Receives MHLW Nod for Label Expansion
    Zacks14 hours ago

    Regeneron's Dupixent Receives MHLW Nod for Label Expansion

    Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.

  • Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.
    Motley Foolyesterday

    Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.

    Find out why shareholders had to endure a roller-coaster ride to nowhere.

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018
    Market Realist7 days ago

    Repatha Could Significantly Drive Amgen’s Revenue Growth in 2018

    How Is Amgen Positioned for 2018?

  • Barrons.com12 days ago

    That Biotech M&A Wave? More like a Trickle

    Large cap biotech companies held a number of meetings with analysts and investors to discuss their plans for 2018, while both Celgene (CELG) and Regeneron (REGN) pre-announced 2017 results that were in-line to positive, compared to consensus estimates. Leerink's Geoffrey Porges and Bradley Canino take a look at the week in biotech, writing that Celgene and Regeneron were "predictably cautious" in their guidance, while the sector largely declined to estimate how tax changes will affect their profits just yet, although most companies have said that the tax bill is mostly positive. Porges and Canino write that big biotechs (save Regeneron) continue to suggest that acquisitions or licensing deals are on the table, as a means to juice pipelines, however no management teams "seemed convincing about having a firm idea of direction, size or type of transaction," leading them to believe that there won't be a big wave of M&A as a result of the tax bill: While a lack of capital may have stymied deals before, now management teams' lack of conviction, higher prices for takeout targets, and uncertainty about the future are the main obstacles.

  • Cramer's lightning round: People might be bailing on Regeneron, but it's a buy
    CNBC12 days ago

    Cramer's lightning round: People might be bailing on Regeneron, but it's a buy

    Jim Cramer zoomed through his take on callers' favorite stocks, including a pharmaceutical name spooking investors.

  • Can Biotech Keep Last Year's Momentum Alive in 2018?
    Zacks13 days ago

    Can Biotech Keep Last Year's Momentum Alive in 2018?

    The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

  • How Mylan’s Europe Segment Performed in 3Q17
    Market Realist13 days ago

    How Mylan’s Europe Segment Performed in 3Q17

    Who’s Watching Mylan in January 2018?

  • How Did Bioverativ Perform in 3Q17?
    Market Realist13 days ago

    How Did Bioverativ Perform in 3Q17?

    A Snapshot of Bioverativ's Recent Performance

  • A Look at Ionis Pharmaceuticals’ January 2018 Valuation
    Market Realist13 days ago

    A Look at Ionis Pharmaceuticals’ January 2018 Valuation

    What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals

  • Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
    Zacks14 days ago

    Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

    Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

  • The Wall Street Journal14 days ago

    Finally, a Cure for Legalese

    One drug industry innovation that investors will surely appreciate: new ways of presenting tedious disclaimers before a company's presentation.

  • How’s Incyte’s Valuation in January 2018?
    Market Realist15 days ago

    How’s Incyte’s Valuation in January 2018?

    New Insights for Incyte Corporation as of JanuaryA look at Incyte

  • Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
    Zacks15 days ago

    Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

    Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

  • See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN

  • The Wall Street Journal15 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Reuters15 days ago

    Regeneron forms consortium to accelerate gene sequencing project

    Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates. The data will be made available to health researchers anywhere in the world following a six-to-12-month period of exclusive access by consortium members, Regeneron said. "This is the first case where there will be large-scale human sequencing linked to large-scale human medical records that will also be publicly available," Regeneron President and Chief Scientific Officer George Yancopoulos said in a telephone interview.

  • Reuters16 days ago

    Sanofi and Regeneron boost investment in cancer drug cemiplimab

    France's Sanofi (SASY.PA) and U.S Regeneron (REGN.O) said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers. In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the United States and Europe to treat eczema and undergoing tests to help treat asthma, nasal polyps, eosinophilic esophagitis and food allergies. "The investment in cemiplimab will be increased to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement and Sanofi and Regeneron will continue to equally fund cemiplimab development," the two groups said.

  • What Are Analysts Saying About Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Future?
    Simply Wall St.16 days ago

    What Are Analysts Saying About Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Future?

    In September 2017, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its latest earnings update, which signalled that the company benefited from a strong tailwind, eventuating to a double-digit earnings growth of 40.79%.Read More...

  • Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
    Zacks20 days ago

    Momenta & Mylan to Initiate Trial on Biosimilar of Eylea

    Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.

  • Reuters20 days ago

    Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

    Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday. If successful, it would likely mark the first competition from a cheaper biosimilar of Eylea, although Regeneron says it has U.S. patent protection on the treatment until 2023. Germany's Formycon AG is far along in testing a biosimilar to Eylea rival Lucentis from Roche.

  • Does Regeneron Pharma Have A Potential Blockbuster In 2018?
    Investor's Business Daily21 days ago

    Does Regeneron Pharma Have A Potential Blockbuster In 2018?

    Regeneron is on deck to launch several drugs with blockbuster potential over the next few years, including a skin cancer treatment in 2018.